XFOR

X4 Pharmaceuticals, Inc. [XFOR] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

XFOR Stock Summary

Top 10 Correlated ETFs

XFOR


Top 10 Correlated Stocks

XFOR


In the News

08:00 29 Mar 2024 XFOR

X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024

BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the fourth-quarter and full year ended December 31, 2023 and providing corporate updates on Thursday, March 21, 2024.

11:43 29 Mar 2024 XFOR

X4: Dip Following Mixed Results In Chronic Neutropenia Indication Worth Buying

X4 Pharmaceuticals has dipped considerably following updated results presented in ASH suggesting that mavorixafor may not be effective as monotherapy in chronic neutropenia (excluding WHIM). Mavorixafor will likely still have a role in chronic neutropenia as add-on to G-CSF. Mavorixafor can enable reductions in G-CSF dosing, which can improve tolerability and is meaningful for patients. FDA has granted priority review for mavorixafor in WHIM, with a PDUFA date of April 30, 2024, and a potential PRV worth $100M upon approval.

08:00 29 Mar 2024 XFOR

X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences

BOSTON, Nov. 10, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in fireside chats at the upcoming Stifel Healthcare Conference being held in New York City, from November 14-15, 2023, and the Piper Sandler 35th Annual Healthcare Conference being held in New York City, from November 28-30, 2023.

12:37 29 Mar 2024 XFOR

X4 Pharmaceuticals, Inc. (XFOR) Q3 2023 Earnings Call Transcript

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Dan Ferry – LifeSci Advisors Paula Ragan – Chief Executive Officer Mark Baldry – Chief Commercial Officer Christophe Arbet-Engels – Chief Medical Officer Adam Mostafa – Chief Financial Officer Conference Call Participants Eva Privitera – TD Cowen Stephen Willey – Stifel Edward Tenthoff – Piper Sandler Andy Fleszar – B. Riley Securities Kristen Kluska – Cantor Fitzgerald Swayampakula Ramakanth – H.C.

08:00 29 Mar 2024 XFOR

X4 Pharmaceuticals to Report Third-Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 9, 2023

BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the third quarter ended September 30, 2023 and providing corporate updates on Thursday, November 9, 2023.

08:00 29 Mar 2024 XFOR

X4 Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in a fireside chat at the upcoming Cantor Global Healthcare Conference being held in New York City, from September 26-28, 2023.

08:01 29 Mar 2024 XFOR

X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023

BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc.  (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the second quarter ended June 30, 2023, and providing corporate and clinical program updates on Thursday, August 10, 2023.

07:35 29 Mar 2024 XFOR

X4 Pharmaceuticals, Inc. (XFOR) Q1 2023 Earnings Call Transcript

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Dr. Paula Ragan - President and CEO Adam Mostafa - CFO Mark Baldry - Chief Commercial Officer Conference Call Participants William Wood - B. Riley Securities Eva Privitera - TD Cowen Swayampakula Ramakanth - Wainwright Rick Miller - Cantor Fitzgerald Operator Greetings, and welcome to X4 Pharmaceuticals' First Quarter 2023 Earnings Conference Call.

08:01 29 Mar 2024 XFOR

X4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023

BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the first quarter ended March 31, 2023 on Thursday, May 4, 2023.

10:58 29 Mar 2024 XFOR

X4 Pharmaceuticals shares lift as investors await new data from WHIM syndrome study

X4 Pharmaceuticals, the Boston-based drug developer, saw its stock trading higher on Wednesday as investors gear up for new results from a Phase 3 trial of its oral cxcr4 antagonist, mavorixafor, for treatment of patients with WHIM syndrome. The firm will present new data at the Annual Meeting of the Clinical Immunology Society (CIS), which is taking place May 18-21, 2023, in St.

XFOR Financial details

Company Rating
Neutral
Market Cap
244.24M
Income
-132.86M
Revenue
0
Book val./share
0.26
Cash/share
0.58
Dividend
-
Dividend %
-
Employees
93
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-1.17
Forward P/E
-3.97
PEG
0.24
P/S
-
P/B
2.39
P/C
2.4
P/FCF
-1.52
Quick Ratio
5.59
Current Ratio
5.81
Debt / Equity
1.09
LT Debt / Equity
1.07
-
-
EPS (TTM)
-0.77
EPS next Y
-0.35
EPS next Q
-0.15
EPS this Y
-61.49%
EPS next Y
-55.07%
EPS next 5Y
-102.6%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
722.22%
-
-
-
-
SMA20
35.11%
SMA50
56.79%
SMA100
60.76%
Inst Own
46.28%
Inst Trans
0.59%
ROA
-79%
ROE
-217%
ROC
-0.69%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-53%
Shs Outstand
167.94M
Shs Float
121.91M
-
-
-
-
Target Price
3.67
52W Range
0.572-2.575
52W High
-
52W Low
-
RSI
72.43
Rel Volume
2.59
Avg Volume
1.67M
Volume
4.33M
Perf Week
43.18%
Perf Month
47.15%
Perf Quarter
47.39%
Perf Half Y
31.13%
-
-
-
-
Beta
0.437
-
-
Volatility
0.15%, 0.2%
Prev Close
-1.42%
Price
1.39
Change
-6.71%

XFOR Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00.15000
Net income per share
-4.91-3.09-3.44-1.48-0.57
Operating cash flow per share
-4.17-2.93-2.75-1.21-0.54
Free cash flow per share
-4.18-3-2.78-1.22-0.54
Cash per share
10.943.923.181.920.64
Book value per share
11.213.632.51.170.29
Tangible book value per share
8.862.281.830.890.19
Share holders equity per share
11.213.632.51.170.29
Interest debt per share
2.172.051.690.670.35
Market cap
123.37M129.1M58.97M63.08M149.1M
Enterprise value
20.1M88.84M16.96M-20.22M107.91M
P/E ratio
-2.18-2.08-0.66-0.67-1.47
Price to sales ratio
043.03000
POCF ratio
-2.57-2.19-0.83-0.82-1.54
PFCF ratio
-2.56-2.15-0.82-0.82-1.54
P/B Ratio
0.951.770.920.852.92
PTB ratio
0.951.770.920.852.92
EV to sales
029.61000
Enterprise value over EBITDA
-0.46-1.48-0.260.23-1.02
EV to operating cash flow
-0.42-1.51-0.240.26-1.12
EV to free cash flow
-0.42-1.48-0.240.26-1.12
Earnings yield
-0.46-0.48-1.5-1.49-0.68
Free cash flow yield
-0.39-0.47-1.21-1.22-0.65
Debt to equity
0.180.530.620.521.09
Debt to assets
0.140.310.340.250.38
Net debt to EBITDA
2.350.670.640.940.39
Current ratio
13.686.976.275.765.34
Interest coverage
-24.08-22.27-23.37-21.93-18.61
Income quality
0.910.950.80.820.95
Dividend Yield
0.160.1000
Payout ratio
-0.35-0.2000
Sales general and administrative to revenue
06.98000
Research and developement to revenue
013.98000
Intangibles to total assets
0.170.220.150.110.12
Capex to operating cash flow
00.020.0100
Capex to revenue
0-0.45000
Capex to depreciation
-1.69-3.88-1.23-0.2-0.03
Stock based compensation to revenue
01.81000
Graham number
35.1815.8913.926.231.92
ROIC
-0.36-0.52-0.77-0.75-0.98
Return on tangible assets
-0.42-0.65-0.89-0.68-0.78
Graham Net
8.341.461.150.650.11
Working capital
119.83M71.36M73.86M106.35M99.21M
Tangible asset value
102.11M45.69M47.06M56.7M33.75M
Net current asset value
97.8M33.24M35.11M47.14M25.92M
Invested capital
0.180.530.620.521.09
Average receivables
2.43M1.46M832K949.5K857K
Average payables
1.32M2.62M3.71M6.03M8.36M
Average inventory
00000
Days sales outstanding
0111.57000
Days payables outstanding
1.13K0826.271.42K1.64K
Days of inventory on hand
00000
Receivables turnover
03.27000
Payables turnover
0.3200.440.260.22
Inventory turnover
00000
ROE
-0.44-0.85-1.38-1.27-1.98
Capex per share
-0.02-0.07-0.0200

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q1

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.16-0.33-0.33-0.01-0.1
Operating cash flow per share
-0.18-0.13-0.13-0.11-0.14
Free cash flow per share
-0.18-0.13-0.13-0.11-0.14
Cash per share
0.640.840.840.720.58
Book value per share
0.350.40.40.340.26
Tangible book value per share
0.240.30.30.260.17
Share holders equity per share
0.350.40.40.340.26
Interest debt per share
0.260.230.230.30.29
Market cap
144.95M146.8M327.35M214.72M166.67M
Enterprise value
88.47M47.25M227.8M141.42M125.48M
P/E ratio
-1.51-0.66-1.47-23.29-2.18
Price to sales ratio
00000
POCF ratio
-5.47-6.85-15.28-10.31-6.01
PFCF ratio
-5.47-6.85-15.27-10.31-6
P/B Ratio
2.82.174.853.183.26
PTB ratio
2.82.174.853.183.26
EV to sales
00000
Enterprise value over EBITDA
-3.02-1.83-8.83-5.5-4.99
EV to operating cash flow
-3.34-2.21-10.63-6.79-4.52
EV to free cash flow
-3.34-2.2-10.63-6.79-4.52
Earnings yield
-0.17-0.38-0.17-0.01-0.11
Free cash flow yield
-0.18-0.15-0.07-0.1-0.17
Debt to equity
0.710.550.550.861.09
Debt to assets
0.30.210.210.340.38
Net debt to EBITDA
1.933.863.862.851.64
Current ratio
5.046.646.645.815.34
Interest coverage
-20.66-22.48-22.48-16.65-13.36
Income quality
1.10.380.389.041.45
Dividend Yield
00.5000
Payout ratio
0-1.32000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.140.10.10.10.12
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
-0.07-0.06-0.06-0.08-0.56
Stock based compensation to revenue
00000
Graham number
1.141.721.720.30.75
ROIC
-0.25-0.24-0.24-0.21-0.23
Return on tangible assets
-0.22-0.36-0.36-0.01-0.15
Graham Net
0.150.210.210.180.09
Working capital
78.74M125.4M125.4M122.44M99.21M
Tangible asset value
34.33M50.18M50.18M50.24M33.75M
Net current asset value
25.49M41.79M41.79M42.17M25.92M
Invested capital
0.710.550.550.861.09
Average receivables
905K739K820K606.5K477.5K
Average payables
6.88M5.55M5.11M6.62M8.54M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
1.08K897.89890.931.46K12.99K
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
0.080.10.10.060.01
Inventory turnover
00000
ROE
-0.46-0.82-0.82-0.03-0.37
Capex per share
00000

XFOR Frequently Asked Questions

What is X4 Pharmaceuticals, Inc. stock symbol ?

X4 Pharmaceuticals, Inc. is a US stock , located in Boston of Ma and trading under the symbol XFOR

Is X4 Pharmaceuticals, Inc. buy or a sell ?